Craig Lindsley

October 22, 2020

Lindsley to direct Center for Neuroscience Drug Discovery

Craig Lindsley, PhD, the William K. Warren Jr. Chair in Medicine and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery (WCNDD), effective Dec. 1. Lindsley assumes the director position from Jeffrey Conn, PhD, Lee. E. Limbird Chair in Pharmacology and professor of Pharmacology.

By VUMC News and Communications
January 24, 2019

American Chemical Society honors Lindsley’s research

The year is starting off with a bang for Craig Lindsley, PhD, director of medicinal chemistry in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD).

By Bill Snyder
January 10, 2019

Lindsley receives ASPET award honoring drug discovery research

Craig Lindsley, PhD, a leader of Vanderbilt University School of Medicine’s groundbreaking drug discovery program, is being honored by the American Society for Pharmacology and Experimental Therapeutics (ASPET) for his transformative approaches to identifying potential new drugs.

By Bill Snyder
December 20, 2018

Lindsley named fellow of National Academy of Inventors

Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the National Academy of Inventors (NAI).

By Bill Snyder
July 12, 2018

Vanderbilt licenses compound to Nashville’s Appello to advance Parkinson’s therapies

Vanderbilt University has signed a licensing agreement with Nashville-based start-up Appello Pharmaceuticals, Inc. to advance novel compounds developed by researchers in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) for the treatment of Parkinson’s disease.

By VUMC News and Communications
February 1, 2018

AAAS, chemistry society honor Lindsley’s research contributions

Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the Royal Society of Chemistry and elected chair-elect of the Section of Pharmaceutical Sciences of the American Association for the Advancement of Science (AAAS).

By Bill Snyder
December 7, 2017

Vanderbilt researchers’ papers among those most cited

Eight current faculty members at Vanderbilt have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
By Bill Snyder
December 7, 2017

Lindsley honored by Pharmaceutical Society of Japan

Craig Lindsley, PhD, the William K. Warren Jr. Professor of Medicine at Vanderbilt, is the 2018 recipient of the Sato Memorial International Award of the Pharmaceutical Society of Japan.
By Bill Snyder
September 21, 2017

University of Kansas honors Lindsley’s pharmacology research

Craig Lindsley, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been honored by the University of Kansas with the 2018 Edward E. Smissman Lectureship for his outstanding contributions to the fields of medicinal chemistry and molecular pharmacology.
By Bill Snyder
August 7, 2017

Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
By Bill Snyder
May 25, 2017

Vanderbilt, Ono Pharmaceutical extend drug discovery agreement

Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019.
By VUMC News and Communications
January 12, 2017

Lindsley’s drug discovery efforts land ASPET Award

Craig Lindsley, Ph.D., a leader of Vanderbilt University School of Medicine’s groundbreaking drug discovery program, is the 2017 recipient of the Pharmacia-ASPET Award in Experimental Therapeutics from the American Society for Pharmacology and Experimental Therapeutics (ASPET).
By Bill Snyder
December 27, 2016

Investigational new drug for Alzheimer’s scheduled for first study in humans

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
By Craig Boerner
1 2 3